THE BEST SIDE OF AGO TUMOR

Molecular typing relies on molecular genetic tests and is not yet routinely available. Molecular subtypes and immunohistochemical surrogate markers in the tumors (HR, HER2, triple negative) correlate in about 70%. The differentiation of luminal A and B subtypes by HR status and proliferation markers like Ki-sixty seven may be helpful, but a future